Shanghai Jeyou Pharmaceutical Co., Ltd. (上海知信药业股份有限公司) is a Shanghai-based pharmaceutical company engaged in the research, development, manufacturing, and commercialization of therapeutic medicines in China.
The company participates across the drug development lifecycle and works with domestic and international partners through collaboration and licensing agreements. Its operations align with China’s regulatory standards for pharmaceuticals, with activities spanning R&D and compliant production of finished formulations.
None yet. When a new project in the record names Shanghai Jeyou Pharmaceutical as owner, partner or investor, it shows here.
GSK acquires ozureprubart, a potential long-acting anti-IgE therapy for food allergies, with phase IIb data expected in 2027. The deal is valued at $2.2 billion.
